AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn. The agreement will give AbbVie access to Capstan’s lead CAR-T therapy ...

AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure We continue to believe AbbVie needs to expand its late-stage pipeline.

There’s really no such thing as a “no brainer” stock pick. I’d say that some opportunities are more compelling than others.

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion.

AbbVie raised its 2027 combined sales guidance for these assets to over $31 billion, driven by strong share capture and market expansion.

AbbVie’s focus on building a strong portfolio, particularly in immunology and neurology, further supports the Buy rating. The company’s plans to enhance its offering with promising trial ...

AbbVie forecasts 7% growth in 2025 and 10-11% in 2026-2027 for its immunology segment. Goldman Sachs raises AbbVie’s price target to $208, citing Skyrizi and Rinvoq as key growth drivers.

AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs ...

AbbVie has announced that it will be expanding its immunology pipeline by acquiring Nimble Therapeutics for $200m. The deal gives AbbVie access to Nimble’s lead asset, an investigational oral peptide ...